Symbols / ABOS
ABOS Chart
About
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 167.18M |
| Enterprise Value | 71.41M | Income | -133.35M | Sales | — |
| Book/sh | 1.54 | Cash/sh | 2.09 | Dividend Yield | — |
| Payout | 0.00% | Employees | 61 | IPO | — |
| P/E | — | Forward P/E | -1.43 | PEG | — |
| P/S | — | P/B | 1.79 | P/C | — |
| EV/EBITDA | -0.52 | EV/Sales | — | Quick Ratio | 5.80 |
| Current Ratio | 6.02 | Debt/Eq | 33.09 | LT Debt/Eq | — |
| EPS (ttm) | -2.21 | EPS next Y | -1.94 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-24 | ROA | -42.23% |
| ROE | -85.93% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 60.57M |
| Shs Float | 35.16M | Short Float | 2.00% | Short Ratio | 0.76 |
| Short Interest | — | 52W High | 3.05 | 52W Low | 0.85 |
| Beta | 0.24 | Avg Volume | 586.39K | Volume | 234.08K |
| Target Price | $7.00 | Recom | None | Prev Close | $2.58 |
| Price | $2.76 | Change | 6.98% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.00
Mean price target
2. Current target
$2.76
Latest analyst target
3. DCF / Fair value
$-23.46
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.76
Low
$4.00
High
$10.00
Mean
$7.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-01-27 | main | BTIG | Buy → Buy | $7 |
| 2025-11-18 | main | B of A Securities | Buy → Buy | $8 |
| 2025-08-25 | main | B of A Securities | Buy → Buy | $9 |
| 2025-06-17 | init | Citigroup | — → Buy | $4 |
| 2025-03-28 | main | UBS | Buy → Buy | $4 |
| 2025-03-28 | main | HC Wainwright & Co. | Buy → Buy | $11 |
| 2024-11-13 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-10-03 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-08-15 | main | UBS | Buy → Buy | $6 |
| 2024-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-07-25 | init | Citigroup | — → Buy | $7 |
| 2024-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-03-31 | main | UBS | Buy → Buy | $14 |
| 2024-03-27 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-12-12 | init | Deutsche Bank | — → Buy | $8 |
| 2023-08-09 | reit | Credit Suisse | Outperform → Outperform | $13 |
| 2023-08-09 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-07-17 | reit | Cantor Fitzgerald | Overweight → Overweight | $13 |
| 2023-07-17 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2023-05-18 | init | Cantor Fitzgerald | — → Overweight | $13 |
- B of A Securities Maintains Acumen Pharmaceuticals (ABOS) Buy Recommendation - Nasdaq ue, 18 Nov 2025 08
- Insider Sale: President and CDO of $ABOS Sells 6,467 Shares | ABOS Stock News - Quiver Quantitative Fri, 09 Jan 2026 08
- Meisner, Acumen Pharmaceuticals CLO, sells $91k in ABOS stock - Investing.com Mon, 12 Jan 2026 08
- Does Sabirnetug’s Phase 2 Extension and Insider Stock Sales Alter the Bull Case for ABOS? - Yahoo Finance Mon, 26 Jan 2026 08
- Acumen (NASDAQ: ABOS) reports CTAD results on 15 to 68-fold delivery and ALTITUDE-AD recruitment - Stock Titan ue, 02 Dec 2025 08
- Promising Penny Stocks To Watch In September 2025 - simplywall.st ue, 30 Sep 2025 07
- Analysts Are Bullish on These Healthcare Stocks: vTv Therapeutics (VTVT), Acumen Pharmaceuticals (ABOS) - The Globe and Mail ue, 03 Feb 2026 08
- 2 ‘Strong Buy’ Stocks That Wall Street Believes Can Soar 360% to 780% - Barchart.com ue, 23 Sep 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Sun, 17 Mar 2024 19
- Acumen Pharma CMO Siemers sells $21k in ABOS stock - Investing.com Wed, 07 Jan 2026 08
- 12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga Mon, 26 Jan 2026 08
- Acumen Updates Investor Presentation, Highlights 2026 Alzheimer’s Milestones - TipRanks Mon, 12 Jan 2026 08
- Acumen Pharmaceuticals (ABOS) Price Target Increased by 11.84% to 8.67 - Nasdaq ue, 30 Sep 2025 07
- Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks - Yahoo Finance Sun, 25 Jan 2026 08
- Are Insider Tax-Related Sales Misaligned With Acumen Pharmaceuticals’ (ABOS) Alzheimer’s Trial Progress Narrative? - simplywall.st ue, 27 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 17756 | 39394 | — | Sale at price 2.08 - 3.00 per share. | MEISNER DEREK M | Officer | — | 2026-01-28 00:00:00 | D |
| 1 | 17756 | 32849 | — | Conversion of Exercise of derivative security at price 1.85 per share. | MEISNER DEREK M | Officer | — | 2026-01-28 00:00:00 | D |
| 2 | 8934 | 16721 | — | Sale at price 1.81 - 1.90 per share. | MEISNER DEREK M | Officer | — | 2026-01-23 00:00:00 | D |
| 3 | 12035 | 21993 | — | Sale at price 1.81 - 1.88 per share. | O'CONNELL DANIEL JOSEPH | Chief Executive Officer | — | 2026-01-22 00:00:00 | D |
| 4 | 3226 | 5833 | — | Sale at price 1.80 - 1.82 per share. | SIEMERS ERIC M.D. | Officer | — | 2026-01-22 00:00:00 | D |
| 5 | 2777 | 5031 | — | Sale at price 1.81 - 1.84 per share. | BARTON RUSSELL | Chief Operating Officer | — | 2026-01-22 00:00:00 | D |
| 6 | 4160 | 7607 | — | Sale at price 1.81 - 1.86 per share. | WILLIAM MATTHEW ZUGA | Chief Financial Officer | — | 2026-01-22 00:00:00 | D |
| 7 | 299800 | — | — | Stock Award(Grant) at price 0.00 per share. | O'CONNELL DANIEL JOSEPH | Chief Executive Officer | — | 2026-01-20 00:00:00 | D |
| 8 | 99133 | — | — | Stock Award(Grant) at price 0.00 per share. | SIEMERS ERIC M.D. | Officer | — | 2026-01-16 00:00:00 | D |
| 9 | 84600 | — | — | Stock Award(Grant) at price 0.00 per share. | BARTON RUSSELL | Chief Operating Officer | — | 2026-01-16 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -99.67M | -50.25M | -42.69M | 61.58M |
| TotalUnusualItems | 1.59M | -1.36M | -81.16M | |
| TotalUnusualItemsExcludingGoodwill | 1.59M | -1.36M | -81.16M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -102.33M | -52.37M | -42.86M | -100.61M |
| ReconciledDepreciation | 178.00K | 184.00K | 169.00K | 4.00K |
| EBITDA | -98.08M | -51.61M | -42.69M | -19.58M |
| EBIT | -98.26M | -51.79M | -42.86M | -19.58M |
| NetInterestIncome | 10.25M | 10.21M | 2.39M | 84.00K |
| InterestExpense | 4.07M | 581.00K | 0.00 | |
| InterestIncome | 14.32M | 10.79M | 2.39M | 84.00K |
| NormalizedIncome | -103.92M | -51.01M | -42.86M | -19.45M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -102.33M | -52.37M | -42.86M | -100.61M |
| TotalExpenses | 114.02M | 61.14M | 45.24M | 19.58M |
| TotalOperatingIncomeAsReported | -114.02M | -61.14M | -45.24M | -19.58M |
| DilutedAverageShares | 60.01M | 48.61M | 40.60M | 20.06M |
| BasicAverageShares | 60.01M | 48.61M | 40.60M | 20.06M |
| DilutedEPS | -1.71 | -1.08 | -1.06 | -5.02 |
| BasicEPS | -1.71 | -1.08 | -1.06 | -5.02 |
| DilutedNIAvailtoComStockholders | -102.33M | -52.37M | -42.86M | -100.61M |
| NetIncomeCommonStockholders | -102.33M | -52.37M | -42.86M | -100.61M |
| NetIncome | -102.33M | -52.37M | -42.86M | -100.61M |
| NetIncomeIncludingNoncontrollingInterests | -102.33M | -52.37M | -42.86M | -100.61M |
| NetIncomeContinuousOperations | -102.33M | -52.37M | -42.86M | -100.61M |
| PretaxIncome | -102.33M | -52.37M | -42.86M | -100.61M |
| OtherIncomeExpense | 1.44M | -1.44M | -11.00K | -81.11M |
| OtherNonOperatingIncomeExpenses | -151.00K | -83.00K | -11.00K | 51.00K |
| GainOnSaleOfSecurity | 1.59M | -1.36M | -81.16M | |
| NetNonOperatingInterestIncomeExpense | 10.25M | 10.21M | 2.39M | 84.00K |
| InterestExpenseNonOperating | 4.07M | 581.00K | 0.00 | |
| InterestIncomeNonOperating | 14.32M | 10.79M | 2.39M | 84.00K |
| OperatingIncome | -114.02M | -61.14M | -45.24M | -19.58M |
| OperatingExpense | 114.02M | 61.14M | 45.24M | 19.58M |
| ResearchAndDevelopment | 93.80M | 42.32M | 32.36M | 12.30M |
| SellingGeneralAndAdministration | 20.22M | 18.82M | 12.88M | 7.28M |
| GeneralAndAdministrativeExpense | 20.22M | 18.82M | 12.88M | 7.28M |
| OtherGandA | 20.22M | 18.82M | 12.88M | 7.28M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 60.09M | 57.91M | 41.03M | 40.47M |
| ShareIssued | 60.09M | 57.91M | 41.03M | 40.47M |
| TotalDebt | 28.73M | 28.49M | 105.00K | 0.00 |
| TangibleBookValue | 181.74M | 266.80M | 188.78M | 225.18M |
| InvestedCapital | 210.26M | 294.31M | 188.78M | 225.18M |
| WorkingCapital | 150.70M | 233.64M | 172.52M | 193.51M |
| NetTangibleAssets | 181.74M | 266.80M | 188.78M | 225.18M |
| CapitalLeaseObligations | 283.00K | 1.15M | 105.00K | 0.00 |
| CommonStockEquity | 181.82M | 266.97M | 188.78M | 225.18M |
| TotalCapitalization | 210.26M | 294.31M | 188.78M | 225.18M |
| TotalEquityGrossMinorityInterest | 181.82M | 266.97M | 188.78M | 225.18M |
| StockholdersEquity | 181.82M | 266.97M | 188.78M | 225.18M |
| GainsLossesNotAffectingRetainedEarnings | -48.00K | 312.00K | -751.00K | -231.00K |
| OtherEquityAdjustments | -48.00K | 312.00K | -751.00K | -231.00K |
| RetainedEarnings | -325.13M | -222.80M | -170.43M | -127.57M |
| AdditionalPaidInCapital | 506.99M | 489.45M | 359.95M | 352.98M |
| CapitalStock | 6.00K | 6.00K | 4.00K | 4.00K |
| CommonStock | 6.00K | 6.00K | 4.00K | 4.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 57.18M | 43.15M | 7.81M | 5.15M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 29.57M | 30.18M | 0.00 | 0.00 |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 0.00 | ||
| DerivativeProductLiabilities | 970.00K | 2.56M | ||
| EmployeeBenefits | 0.00 | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 28.60M | 27.62M | 0.00 | |
| LongTermCapitalLeaseObligation | 150.00K | 284.00K | 0.00 | |
| LongTermDebt | 28.45M | 27.34M | ||
| CurrentLiabilities | 27.61M | 12.97M | 7.81M | 5.15M |
| OtherCurrentLiabilities | 230.00K | 212.00K | 131.00K | 204.00K |
| CurrentDebtAndCapitalLeaseObligation | 133.00K | 866.00K | 105.00K | |
| CurrentCapitalLeaseObligation | 133.00K | 866.00K | 105.00K | 0.00 |
| PensionandOtherPostRetirementBenefitPlansCurrent | 4.21M | 3.69M | 2.01M | 1.10M |
| PayablesAndAccruedExpenses | 23.04M | 8.20M | 5.57M | 3.84M |
| CurrentAccruedExpenses | 17.39M | 6.82M | 3.93M | 2.75M |
| InterestPayable | 249.00K | 249.00K | 0.00 | |
| Payables | 5.65M | 1.38M | 1.64M | 1.09M |
| AccountsPayable | 5.65M | 1.38M | 1.64M | 1.09M |
| TotalAssets | 238.99M | 310.12M | 196.59M | 230.33M |
| TotalNonCurrentAssets | 60.69M | 63.51M | 16.26M | 31.67M |
| OtherNonCurrentAssets | 295.00K | 243.00K | 151.00K | 14.00K |
| NonCurrentPrepaidAssets | 9.00K | 42.00K | ||
| InvestmentsAndAdvances | 59.97M | 62.55M | 15.84M | 31.62M |
| InvestmentinFinancialAssets | 59.97M | 62.55M | 15.84M | 31.62M |
| AvailableForSaleSecurities | 59.97M | 62.55M | 15.84M | 31.62M |
| GoodwillAndOtherIntangibleAssets | 75.00K | 169.00K | ||
| OtherIntangibleAssets | 75.00K | 169.00K | ||
| NetPPE | 339.00K | 503.00K | 270.00K | 36.00K |
| GrossPPE | 339.00K | 503.00K | 270.00K | 36.00K |
| OtherProperties | 339.00K | 503.00K | 270.00K | 36.00K |
| CurrentAssets | 178.31M | 246.62M | 180.33M | 198.66M |
| OtherCurrentAssets | 5.33M | 1.96M | 1.42M | 2.83M |
| PrepaidAssets | 1.02M | 905.00K | 1.30M | 1.60M |
| Receivables | 398.00K | 225.00K | 0.00 | 0.00 |
| OtherReceivables | 345.00K | |||
| AccruedInterestReceivable | 53.00K | 225.00K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 171.56M | 243.52M | 177.60M | 194.24M |
| OtherShortTermInvestments | 135.93M | 176.64M | 47.50M | 72.08M |
| CashAndCashEquivalents | 35.63M | 66.89M | 130.10M | 122.16M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -86.23M | -43.09M | -35.31M | -18.00M |
| RepurchaseOfCapitalStock | -41.00K | 0.00 | ||
| RepaymentOfDebt | -739.00K | 0.00 | ||
| IssuanceOfDebt | 0.00 | 30.00M | 0.00 | |
| IssuanceOfCapitalStock | 7.94M | 121.90M | 3.79M | 198.59M |
| CapitalExpenditure | -16.00K | -21.00K | -161.00K | -40.00K |
| InterestPaidSupplementalData | 2.97M | 169.00K | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 35.86M | 67.12M | 130.10M | 122.16M |
| BeginningCashPosition | 67.12M | 130.10M | 122.16M | 43.78M |
| ChangesInCash | -31.26M | -62.98M | 7.94M | 78.39M |
| FinancingCashFlow | 6.93M | 151.75M | 3.91M | 200.47M |
| CashFlowFromContinuingFinancingActivities | 6.93M | 151.75M | 3.91M | 200.47M |
| NetOtherFinancingCharges | -230.00K | -476.00K | ||
| InterestPaidCFF | 0.00 | -476.00K | ||
| ProceedsFromStockOptionExercised | 0.00 | 325.00K | 115.00K | 1.88M |
| CashDividendsPaid | 0.00 | 0.00 | ||
| NetPreferredStockIssuance | 0.00 | 30.03M | ||
| PreferredStockIssuance | 0.00 | 30.03M | ||
| NetCommonStockIssuance | 7.90M | 121.90M | 3.79M | 168.56M |
| CommonStockPayments | -41.00K | 0.00 | ||
| CommonStockIssuance | 7.94M | 121.90M | 3.79M | 168.56M |
| NetIssuancePaymentsOfDebt | -739.00K | 30.00M | 0.00 | |
| NetLongTermDebtIssuance | -739.00K | 30.00M | 0.00 | |
| LongTermDebtPayments | -739.00K | 0.00 | ||
| LongTermDebtIssuance | 0.00 | 30.00M | 0.00 | |
| InvestingCashFlow | 48.03M | -171.67M | 39.19M | -104.12M |
| CashFlowFromContinuingInvestingActivities | 48.03M | -171.67M | 39.19M | -104.12M |
| NetInvestmentPurchaseAndSale | 48.04M | -171.65M | 39.35M | -104.08M |
| SaleOfInvestment | 218.77M | 78.98M | 80.86M | 0.00 |
| PurchaseOfInvestment | -170.73M | -250.63M | -41.51M | -104.08M |
| NetPPEPurchaseAndSale | -16.00K | -18.00K | -161.00K | -40.00K |
| SaleOfPPE | 0.00 | 3.00K | 0.00 | |
| PurchaseOfPPE | -16.00K | -21.00K | -161.00K | -40.00K |
| OperatingCashFlow | -86.22M | -43.06M | -35.15M | -17.96M |
| CashFlowFromContinuingOperatingActivities | -86.22M | -43.06M | -35.15M | -17.96M |
| ChangeInWorkingCapital | 11.65M | 3.87M | 3.99M | 298.00K |
| ChangeInOtherCurrentLiabilities | -23.00K | 17.00K | -137.00K | 0.00 |
| ChangeInOtherCurrentAssets | 74.00K | -70.00K | -137.00K | -14.00K |
| ChangeInPayablesAndAccruedExpense | 15.26M | 4.29M | 2.56M | 4.19M |
| ChangeInAccruedExpense | 10.99M | 4.55M | 2.01M | 3.64M |
| ChangeInPayable | 4.27M | -261.00K | 552.00K | 557.00K |
| ChangeInAccountPayable | 4.27M | -261.00K | 552.00K | 557.00K |
| ChangeInPrepaidAssets | -3.66M | -369.00K | 1.70M | -3.88M |
| ChangeInReceivables | 0.00 | |||
| OtherNonCashItems | 1.35M | 884.00K | 81.27M | |
| StockBasedCompensation | 9.63M | 6.14M | 3.06M | 922.00K |
| AmortizationOfSecurities | -5.01M | -3.12M | 487.00K | 155.00K |
| DepreciationAmortizationDepletion | 178.00K | 184.00K | 169.00K | 4.00K |
| DepreciationAndAmortization | 178.00K | 184.00K | 169.00K | 4.00K |
| Depreciation | 178.00K | 184.00K | 169.00K | 4.00K |
| OperatingGainsLosses | -1.69M | 1.35M | 81.16M | |
| GainLossOnInvestmentSecurities | -1.69M | 1.35M | 81.16M | |
| NetIncomeFromContinuingOperations | -102.33M | -52.37M | -42.86M | -100.61M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ABOS
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|